PF-06700841 is primarily investigated for its potential therapeutic applications in treating autoimmune and inflammatory diseases. It functions as a dual inhibitor of TYK2 and JAK1, which are key enzymes involved in signaling pathways that regulate immune responses. By targeting these enzymes, PF-06700841 can modulate the activity of cytokines that drive inflammation, making it a promising candidate for conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Clinical trials have explored its efficacy and safety in reducing disease symptoms and improving patient outcomes. Its ability to selectively inhibit specific JAK pathways may also offer a favorable safety profile compared to broader JAK inhibitors. Ongoing research continues to evaluate its potential in other immune-mediated disorders.